Treatment options for human immunodeficiency virus-infected pregnant women

R. S. Sperling; P. Stratton; A. Bardeguez; D. Cotton; H. E. Fox; D. J. Gloeb; B. Gonik; D. V. Landers; H. Minkoff; J. Mitchell; M. J. O'Sullivan; R. R. Viscarello; D. H. Watts

doi:10.1097/00006250-199203000-00024

Treatment options for human immunodeficiency virus-infected pregnant women

R. S. Sperling, P. Stratton, A. Bardeguez, D. Cotton, H. E. Fox, D. J. Gloeb, B. Gonik, D. V. Landers, H. Minkoff, J. Mitchell, M. J. O'Sullivan, R. R. Viscarello, D. H. Watts

Research output: Contribution to journal › Review article › peer-review

41 Scopus citations

Abstract

The increasing seroprevalence of human immunodeficiency viruis (HIV) among women of reproductive age and the risks of vertical transmission of HIV have led to recommendations for routine prenatal HIV counseling and testing. The incentive to undergo such testing is related not only to fetal concerns, but also to the potential benefit of early and comprehensive therapy for women. Treatments that should be considered for use during pregnancy include the antiretroviral agent zidovudine and prophylactic agents to prevent Pneumocystis carinii pneumonia, the most common opportunistic infection seen in patients progressing to AIDS. Assessment of the risks and benefits of these treatments during pregnancy is complex and requires discussions between physician and patient. This paper reviews current information and provides recommendations for incorporating therapies into obstetric practice.

Original language	English
Pages (from-to)	443-448
Number of pages	6
Journal	Obstetrics and Gynecology
Volume	79
Issue number	3
DOIs	https://doi.org/10.1097/00006250-199203000-00024
State	Published - 1992

Access to Document

10.1097/00006250-199203000-00024

Cite this

@article{a46f219533de4357925e24b34cd42561,

title = "Treatment options for human immunodeficiency virus-infected pregnant women",

abstract = "The increasing seroprevalence of human immunodeficiency viruis (HIV) among women of reproductive age and the risks of vertical transmission of HIV have led to recommendations for routine prenatal HIV counseling and testing. The incentive to undergo such testing is related not only to fetal concerns, but also to the potential benefit of early and comprehensive therapy for women. Treatments that should be considered for use during pregnancy include the antiretroviral agent zidovudine and prophylactic agents to prevent Pneumocystis carinii pneumonia, the most common opportunistic infection seen in patients progressing to AIDS. Assessment of the risks and benefits of these treatments during pregnancy is complex and requires discussions between physician and patient. This paper reviews current information and provides recommendations for incorporating therapies into obstetric practice.",

author = "Sperling, {R. S.} and P. Stratton and A. Bardeguez and D. Cotton and Fox, {H. E.} and Gloeb, {D. J.} and B. Gonik and Landers, {D. V.} and H. Minkoff and J. Mitchell and O'Sullivan, {M. J.} and Viscarello, {R. R.} and Watts, {D. H.}",

year = "1992",

doi = "10.1097/00006250-199203000-00024",

language = "English",

volume = "79",

pages = "443--448",

journal = "Obstetrics and Gynecology",

issn = "0029-7844",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "3",

}

TY - JOUR

T1 - Treatment options for human immunodeficiency virus-infected pregnant women

AU - Sperling, R. S.

AU - Stratton, P.

AU - Bardeguez, A.

AU - Cotton, D.

AU - Fox, H. E.

AU - Gloeb, D. J.

AU - Gonik, B.

AU - Landers, D. V.

AU - Minkoff, H.

AU - Mitchell, J.

AU - O'Sullivan, M. J.

AU - Viscarello, R. R.

AU - Watts, D. H.

PY - 1992

Y1 - 1992

N2 - The increasing seroprevalence of human immunodeficiency viruis (HIV) among women of reproductive age and the risks of vertical transmission of HIV have led to recommendations for routine prenatal HIV counseling and testing. The incentive to undergo such testing is related not only to fetal concerns, but also to the potential benefit of early and comprehensive therapy for women. Treatments that should be considered for use during pregnancy include the antiretroviral agent zidovudine and prophylactic agents to prevent Pneumocystis carinii pneumonia, the most common opportunistic infection seen in patients progressing to AIDS. Assessment of the risks and benefits of these treatments during pregnancy is complex and requires discussions between physician and patient. This paper reviews current information and provides recommendations for incorporating therapies into obstetric practice.

AB - The increasing seroprevalence of human immunodeficiency viruis (HIV) among women of reproductive age and the risks of vertical transmission of HIV have led to recommendations for routine prenatal HIV counseling and testing. The incentive to undergo such testing is related not only to fetal concerns, but also to the potential benefit of early and comprehensive therapy for women. Treatments that should be considered for use during pregnancy include the antiretroviral agent zidovudine and prophylactic agents to prevent Pneumocystis carinii pneumonia, the most common opportunistic infection seen in patients progressing to AIDS. Assessment of the risks and benefits of these treatments during pregnancy is complex and requires discussions between physician and patient. This paper reviews current information and provides recommendations for incorporating therapies into obstetric practice.

UR - http://www.scopus.com/inward/record.url?scp=0026606544&partnerID=8YFLogxK

U2 - 10.1097/00006250-199203000-00024

DO - 10.1097/00006250-199203000-00024

M3 - Review article

C2 - 1738529

AN - SCOPUS:0026606544

SN - 0029-7844

VL - 79

SP - 443

EP - 448

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

IS - 3

ER -

Treatment options for human immunodeficiency virus-infected pregnant women

Abstract

Access to Document

Fingerprint

Cite this